Hillstream's HSB-1216 with pembrolizumab inhibits tumor growth in Calu-1 KRAS G12C-mutated NSCLC cell line

Feb. 13, 2023

Hillstream Biopharma Inc. has announced initial results evaluating the synergy of ferroptosis inducer HSB-1216 (quatramer salinomycin) with anti-PD-1 antibody pembrolizumab in the Calu-1 KRAS G12C-mutated non-small-cell lung cancer (NSCLC) cell line.

BioWorld Science Cancer

Today's news in brief

BioWorld

BioWorld briefs for May 14, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for May 14, 2025.

FDA shift from animal testing fuels organoid, organ-on-chip demand

BioWorld Science

The U.S. FDA’s decision to phase out animal testing for INDs is driving a new market of alternative, nonanimal testing technologies like organoids and...

AI generated, 3D rendering of protein degradation

AACR 2025: Induced proximity strategy, beyond degraders

BioWorld

Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical...

Three med-tech IPOs on the horizon

BioWorld MedTech

April may not have brought rain to med-tech, but tariffs and financial uncertainty certainly dampened the enthusiasm for IPOs. With those clouds lifting, three...